首页> 中文期刊> 《海南医科大学学报(英文版)》 >Effect of kanglaite injection and docetaxel in treating advanced stage esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients

Effect of kanglaite injection and docetaxel in treating advanced stage esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients

         

摘要

Objective:To investigate the effect of Kanglaite injection combined with docetaxel in advanced esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients.Method:A total of 130 patients with advanced esophageal cancer admitted in our hospital from October 2014 to July 2017were selected and divided into two groups according to the time of admission, 65 cases in each group, set as observation group and control group, all patients were treated with conventional radiotherapy (cisplatin combined with 5-fluorouracil), the observation group was given Kanglaite injection combined with docetaxel on the basis of this, while the control group only was given docetaxel treatment, the treatment period was 6 weeks, tumor markers, VEGF and immune function of both group after treatment were compared.Result: After treatment, the levels of carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and carcino-embryonic antigen (CEA) in the observation group were lower than those in the control group, the difference was statistically significant; VEGF level in the observation group after treatment was lower than the control group, the difference was statistically significant; After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while the levels of CD8+ in the observation group was lower than those in the control group, the difference was statistically significant.Conclusion: Kanglaite injection combined with docetaxel in the treatment of elderly patients with advanced esophageal cancer is better, effectively reducing the level of tumor markers and vascular endothelial growth factor, improve immune function, it isworthy of clinical application.

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2018年第6期|33-36|共4页
  • 作者单位

    Department of Thoracic Surgery (Esophagus Ⅱ), First People's Hospital of Huai'an, Huai'an, Jiangsu 223300, China;

    Department of Thoracic Surgery (Esophagus Ⅱ), First People's Hospital of Huai'an, Huai'an, Jiangsu 223300, China;

    Department of Thoracic Surgery (Esophagus Ⅱ), First People's Hospital of Huai'an, Huai'an, Jiangsu 223300, China;

    Department of Thoracic Surgery (Esophagus Ⅱ), First People's Hospital of Huai'an, Huai'an, Jiangsu 223300, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号